Bulletin
Investor Alert

New York Markets Open in:

Feb. 9, 2021, 12:38 p.m. EST

Travel giant TUI bets on summer vacations as COVID-19 vaccines boost a surge in bookings

new
Watchlist Relevance
LEARN MORE

Want to see how this story relates to your watchlist?

Just add items to create a watchlist now:

  • X
    TUI AG (TUI)
  • X
    AstraZeneca PLC (AZN)
  • X
    Pfizer Inc. (PFE)

or Cancel Already have a watchlist? Log In

By Lina Saigol

Summer holidays are back on.

That is the sunny outlook from Tui, which said that it expects a rebound in summer demand and higher prices, as the rapid rollout of the U.K.’s COVID-19 vaccination program gathers pace.

The world’s biggest tour operator said on Tuesday that it expects to run 80% of its normal capacity for this summer, with 2.8 million customers already booked for the season ahead.

Average vacation prices were 20% above their pre-pandemic levels, Tui said, as people splashed out more on higher-level packages. Daily bookings in January were 70% higher compared with December 2020, and the company expects the peak booking period is still to come.

“A look at the historically high savings rate in the EU also underlines that the scope for consumer spending is high,” said Fritz Joussen, chief executive of Tui /zigman2/quotes/207049334/delayed UK:TUI +1.46% . “The significant increase in spending on booked travel reflects this very clearly. Holidaymakers are catching up and are willing to pay more for their holidays.”

Read: Biden to reinstate travel bans amid fears about new variants as global case tally heads toward 100 million

Joussen’s comments come a day after England’s deputy chief medical officer, Prof. Jonathan Van-Tam, told a news conference that it was “too early to say” whether people could begin to start planning summer holidays.

From next week, travelers arriving from countries deemed high risk such as South Africa , where new strains of coronavirus have been identified, will have to quarantine in hotels for 10 days.

Read: COVID-19 hotel quarantine from high-risk countries to start in U.K. from Feb. 15

Russ Mould, analyst at AJ Bell, said Tui was “gambling its fortunes” on a last-minute surge for summer bookings.

“Any major delay to rolling out the vaccine to a younger and more active age group could put significant pressure on its finances, which are already creaking due to very high debt levels,” Mould added.

Shares in Tui, which have fallen by around 40% over the past year, were trading 0.54% lower on Tuesday morning in London, where the company has its primary listing.

More than  10 million people  in the U.K. have already received one dose of either the vaccine developed by U.K.-Swedish drug company AstraZeneca /zigman2/quotes/203048482/delayed UK:AZN -0.46%  with the University of Oxford, or the shot from U.S. drug company Pfizer /zigman2/quotes/202877789/composite PFE +1.16% and its German partner BioNTech /zigman2/quotes/214419716/composite BNTX +6.12% . However, several European Union countries have paused inoculations amid a shortage of supplies in the 27-member bloc.

Read: Pfizer–BioNTech partnership pledges 75 million more vaccine doses to help ease the EU bloc’s shortage

In the three months to the end of December, TUI /zigman2/quotes/206000695/delayed XE:TUI1 +1.12% said revenues fell 88% from €3.85 billion ($4.66 billion) to €468 million, as a result of travel restrictions in its key European markets. The group fell to an underlying loss before interest, tax, depreciation and amortization of €699 million for the quarter, compared with a loss of €147 million for the same period in 2019.

Tui said it had cut its monthly cash outflow to €300 million, from an expected level of €400 to €500 million, and said it had liquidity of €2.1 billion at the beginning of February after a recent state-backed €1.8 billion financial support package, which included a €500 million rights issue.

Analysts at Jefferies cautioned that Tui would suffer from summer cancellations. “We note that the working capital outflow from any cancellations would severely limit liquidity endurance,” they wrote in a note to clients on Tuesday.

/zigman2/quotes/207049334/delayed
UK : U.K.: London
394.90 p
+5.70 +1.46%
Volume: 791,955
April 16, 2021 8:56a
P/E Ratio
N/A
Dividend Yield
0.00%
Market Cap
£4.39 billion
Rev. per Employee
£144,389
loading...
/zigman2/quotes/203048482/delayed
UK : U.K.: London
7,366.00 p
-34.00 -0.46%
Volume: 251,684
April 16, 2021 8:57a
P/E Ratio
38.88
Dividend Yield
2.81%
Market Cap
£95.45 billion
Rev. per Employee
£282,763
loading...
/zigman2/quotes/202877789/composite
US : U.S.: NYSE
$ 37.60
+0.43 +1.16%
Volume: 24.95M
April 15, 2021 4:02p
P/E Ratio
21.99
Dividend Yield
4.15%
Market Cap
$207.34 billion
Rev. per Employee
$533,860
loading...
/zigman2/quotes/214419716/composite
US : U.S.: Nasdaq
$ 140.72
+8.12 +6.12%
Volume: 3.71M
April 15, 2021 4:00p
P/E Ratio
1,343
Dividend Yield
N/A
Market Cap
$32.03 billion
Rev. per Employee
$283,276
loading...
/zigman2/quotes/206000695/delayed
XE : Germany: Xetra
4.53
+0.05 +1.12%
Volume: 554,232
April 16, 2021 9:56a
P/E Ratio
N/A
Dividend Yield
0.00%
Market Cap
€5.05 billion
Rev. per Employee
€164,364
loading...

This Story has 0 Comments
Be the first to comment
More News In
Industries

Story Conversation

Commenting FAQs »

Partner Center

Link to MarketWatch's Slice.